Axo Neurotech

Team 

Dr. Amy Rochford, PhD – CEO and neuroscientist. Holds a PhD from the University of Cambridge, where her research demonstrated that a natural interface approach could restore nerve signals—a discovery that made national headlines and led to a portfolio of patents. She dropped out of a prestigious fellowship to join a Neuralink co-founder as the founding team member at one of the world’s most advanced neurotech startups, helping scale it from 5 to 150 employees and playing a key role in bringing implantable neural devices from concept to patients in under three years.
Email: Amy@axoneurotech.com 

Nathan Jackrazi, MEng – COO and second-time founder. Former SpaceX engineer and one of the first five team members at The Boring Company. Completed a master’s at the University of Cambridge, then left a full-ride PhD to join the founding team at Zipline, where he built the core supply chain team, led FAA production certification, and scaled manufacturing for the world’s largest drone delivery company.
Email: Nathan@axoneurotech.com

Upside

Inevitable Adoption, Expanding Market

Neural interfaces will move from near-zero penetration today (<0.01 % of eligible users) to a routine layer of healthcare and human-machine interaction. Demand spans movement, sensation, communication, cognition, and neuromodulation—already multibillion-dollar therapeutic markets that will compound into much larger segments once a scalable platform
exists.

Biohybrid Advantage 

Axo fuses living cells with flexible electronics, creating regenerative, high-fidelity implants that integrate instead of scar. This delivers signal quality, bandwidth and durability conventional BCIs cannot match.

Capital-Efficient Wedge 

By starting in the peripheral nervous system, where surgery is routine and biology is accessible, we reach first-in-human use in three to four years at a fraction of the capital and risk required for brain-first programs.

Scalable, Ethical Platform 

The same modular interface extends from peripheral nerves to spine to brain to special senses, allowing early clinical wins to unlock larger therapeutic and augmentation markets. Built to be upgradable and accessible, the platform is positioned to lead the field as neural interfaces move from medical solution to universal technology.

Technology

Axo’s implant is a first-of-a-kind biohybrid neural interface: living cells cultured on an ultra-thin, flexible electrode array. The cells integrate with surrounding nerves while the electronics record, stimulate, and transmit signals, creating a self-healing bridge instead of a scar. Animal studies show cleaner signals and greater stability than conventional BCI probes, and seven granted patents lock up every layer from the cell-laden scaffold to the wireless power link.

What makes the platform future-proof is the biological upgrade path. The cell layer can be swapped like software, moving from muscle cells for high-bandwidth prosthetic control to engineered neurons for brain and spinal repair, all while the same electronic backbone and wireless protocol stay in place. The result is a durable, updatable interface that can follow patients through decades of therapeutic use and into the era of everyday human augmentation.

Additional Reading

● Podcast: BCI Guys - The Future of Biohybrid Neural Interfaces with Dr. Amy Rochford
● Paper: When Bio Meets Technology: Biohybrid Neural Interfaces
● Paper: Functional neurological restoration of amputated peripheral nerve using biohybrid regenerative bioelectronics

June 2025